{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:45:20Z","timestamp":1787795120813,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,19]],"date-time":"2018-08-19T00:00:00Z","timestamp":1534636800000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"CSR Foundation"},{"name":"Mishima Kaiun Memorial Foundation"},{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Drug Discovery and Life Science Research"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18am0101084j0002"],"award-info":[{"award-number":["18am0101084j0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jphs.2018.06.014","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T03:38:45Z","timestamp":1535081925000},"page":"359-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells"],"prefix":"10.1016","volume":"137","author":[{"given":"Zhiqi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2018.06.014_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2018.06.014_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jphs.2018.06.014_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jphs.2018.06.014_bib4","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","article-title":"MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy","volume":"11","author":"Finke","year":"2011","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.jphs.2018.06.014_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.jphs.2018.06.014_bib7","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jphs.2018.06.014_bib8","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/eji.200939903","article-title":"Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF","volume":"40","author":"Dolcetti","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","article-title":"Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab","volume":"4","author":"Weber","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jphs.2018.06.014_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jphs.2018.06.014_bib13","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.jphs.2018.06.014_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jphs.2018.06.014_bib15","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.18632\/oncotarget.2289","article-title":"HDAC inhibitors and immunotherapy; a double edged sword?","volume":"5","author":"Kroesen","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jphs.2018.06.014_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ni.2526","article-title":"Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer","volume":"14","author":"Youn","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib17","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1182\/blood-2010-06-287839","article-title":"Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13","volume":"116","author":"Highfill","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2018.06.014_bib18","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1002\/eji.200526172","article-title":"Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in\u00a0vitro","volume":"35","author":"Rossner","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jphs.2015.12.007","article-title":"Unique immunomodulatory effect of paeoniflorin on type I and II macrophages activities","volume":"130","author":"Zhai","year":"2016","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2018.06.014_bib20","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.4049\/jimmunol.0803831","article-title":"IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients","volume":"182","author":"Mandruzzato","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nm1161","article-title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells","volume":"11","author":"Nebbioso","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jphs.2018.06.014_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/eji.201141800","article-title":"Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi","volume":"42","author":"Roulois","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1189\/jlb.0311119","article-title":"Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in\u00a0vitro and in\u00a0vivo","volume":"91","author":"Rosborough","year":"2012","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jphs.2018.06.014_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molimm.2014.08.002","article-title":"Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function","volume":"63","author":"Sahakian","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/B978-0-12-380916-2.00005-X","article-title":"RB1, development, and cancer","volume":"94","author":"Chinnam","year":"2011","journal-title":"Curr Top Dev Biol"},{"key":"10.1016\/j.jphs.2018.06.014_bib26","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.4049\/jimmunol.166.4.2173","article-title":"Cutting edge: stat6-dependent substrate depletion regulates nitric oxide production","volume":"166","author":"Rutschman","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jphs.2018.06.014_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jphs.2018.06.014_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2016.06.217","article-title":"Hypofractionated radiation therapy slashes the immunosuppressive activity on cd8(+)t cell in tumor microenvironment","volume":"96","author":"Lan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jphs.2018.06.014_bib29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1189\/jlb.0708446","article-title":"Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4","volume":"85","author":"Bunt","year":"2009","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jphs.2018.06.014_bib30","first-page":"292","article-title":"Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in\u00a0vitro in a TLR4-independent manner","volume":"9","author":"Michels","year":"2012","journal-title":"J\u00a0Immunot"},{"key":"10.1016\/j.jphs.2018.06.014_bib31","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1073\/pnas.0931259100","article-title":"PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells","volume":"100","author":"Loke","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jphs.2018.06.014_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1247135","article-title":"The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells","volume":"5","author":"Lu","year":"2016","journal-title":"OncoImmunology"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786131830152X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786131830152X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T01:04:20Z","timestamp":1589936660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134786131830152X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S134786131830152X"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2018.06.014","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2018.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}